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Figure: Stoichiometric calibration curve. The HU shift for the 
dosimeter needed for a correct SPR estimation based on the 
curve is indicated with a red arrow. 
Conclusion: The stoichiometric method overestimates the 
measured SPR by 13%. Using DE this error is reduced, to an 
overestimation of 3%. If the stoichiometric method is used for 
the 3D dosimeter its HU must be corrected in the treatment 
planning system.  
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Purpose: Hypothalamic-pituitary axis (HPA) dysfunction is a 
dose-dependent sequela of brain irradiation. Meta-analysis of 
studies on non-pituitary central nervous system tumours 
performed by Appelman-Dijkstra et al. [The Journal of 
Clinical Endocrinology & Metabolism, 8, 2330 (2011)] found 
estimated doses of 25-97 Gy to the HPA and 0.54 prevalence 
of pituitary deficiency. However, no included study reported 
the site-specific doses to the hypothalamus or pituitary. As 
the hypothalamus is thought to be more radiosensitive than 
the pituitary, greater understanding of the structural 
organization and normal tissue tolerances of these two 
structures is necessary to better describe the relationship 
between HPA radiation dose and secondary insufficiency. The 
purpose of this study is to characterize the radiation dose to 
the HPA in adults treated for non-pituitary brain tumours. 
Materials/Methods: Twelve patients, 3 males and 9 females, 
have been enrolled in our prospective VoxTox study that will 
continue to recruit until 2017. Primary diagnoses included 
meningioma (7), pineal tumor (3), and glioma (2). Patients 
were treated with TomoTherapy® and received 50-60 Gy to 
the tumour bed in 30 fractions. Digital Imaging and 
Communications in Medicine radiotherapy data, including 
dose cubes, contours and planning imaging, were retrieved 
from TomoTherapy® archives using an in-house software and 
imported into ProSoma virtual simulation software. Quality 
assurance of hypothalamus and pituitary contours was 
performed. Parametrisation of dosimetric data from planning 
computed tomography scans was used to determine mean 
radiation doses to the hypothalamus and pituitary separately. 
Dose volume histogram data were exported to Matlab®. 
Equivalent uniform doses (EUDs) for a parallel structure (a=1) 
and serial structure (a=20) were calculated utilizing a freely 
available program and normal tissue tolerance parameters 
for the lung and spinal cord, respectively. 
Results: The mean radiation doses to the hypothalamus and 
pituitary were 35 Gy and 34 Gy, respectively. Serial and 
parallel EUDs for each patient are presented in Figure 1. The 
mean EUDs for a=1 and a=20 were 30 Gy (range 14-52) and 33 
Gy (range 19-52), respectively, for the hypothalamus and 29 
(range 8-46) and 31 Gy (range 8-46), respectively, for the 
pituitary. The mean difference between serial and parallel 
EUD values was 3 Gy for both the hypothalamus and the 
pituitary. 
Conclusions: The organization of the hypothalamus and 
pituitary into serial or parallel structures may not be 
predictive of HPA response to radiation. Future studies are 
necessary to isolate the dose-volume effects of these two 
organs.  
 
 
 
Figure 1. EUD doses to the hypothalamus (blue) and pituitary 
(red) are presented for parallel (circle) and serial (triangle) 
structures for each patient. 
 
Keywords: brain tumours; pituitary; hypothalamus 
 
207 
Response-based Bayesian Network Approaches for 
Adaptive Radiotherapy of Non-Small Cell Lung Cancer 
(NSCLC) 
Y. Luo1, I. El Naqa1, D.L. McShan1, I. Lohse1, M.M. Matuszak1, 
M. Schipper1, S. Jolly1, F.M. Kong2, R.K. Ten Haken1  
1 Department of Radiation Oncology, The University of 
Michigan, Ann Arbor, MI, USA 
2 Department of Radiation Oncology, Georgia Regents 
University, Augusta, GA, USA 
 
Purpose:  In NSCLC radiotherapy, personalized radiation 
treatment is intended to deliver an appropriate amount of 
dose to control the tumor while reducing radiation-induced 
toxicities such as radiation pneumonitis, esophagitis, carditis.  
The outcomes of radiation treatment may depend on 
radiation dose and patients’ physical, clinical, biological and 
genomic characteristics before and during the course of 
radiotherapy.  We intend to find hierarchical biophysical 
relationships influencing the observed outcomes from 
retrospective data and develop practical Bayesian Networks 
(BN) for adaptive radiotherapy of the NSCLC. 
Materials/methods:  Our study includes 79 NSCLC patients 
treated on prospective protocols under IRB approval.  In 
addition to dosimetric information, each patient had 179 
features from five categories including clinical factors (10) 
(e.g., age, KPS), cytokines before (30) and during (30) the 
treatment course, microRNAs (49), and single-nucleotide 
polymorphisms (SNPs) (60).  A large-scale Markov blanket 
based on the HITON algorithm is employed for selecting 
relevant biophysical predictors of outcomes.  The 
corresponding BN structure is obtained using the hill-climbing 
algorithm implemented in the R programming environment.  
